Liver Disease: Management of Cirrhosis Flashcards

1
Q

Ascites defn

A

§ Accumulation of fluid in the peritoneal cavity.
§ Several contributing factors including:
–Splanchnic vasodilation
–Increased capillary filtration pressure
–Activation of the renin-angiotensin-aldosterone-system (RAAS)
–Decreased albumin
Lymphatic system is overwhelmed

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Symptoms of Ascites

A

§ Abdominal distension
§ Shortness of breath
§ Weight gain
§ Early satiety

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

goals for ascites tx

A

§ Eliminate symptoms
§ Reduce the volume in fluid in abdomen, but need to very careful not to cause intravascular volume depletion
§ Prevent recurrence

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

treatment for Ascites approaches

A
§ Sodium and fluid restriction
§ Diuretics
§ Albumin
§ Invasive procedures:
–Paracentesis
–TIPS (Transjugular intrahepatic
portosystemic shunt)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Diuretics (3)

Dont need to know dosing for exam

A

Furosemide:
§ Dose: 40 – 160 mg/day
§ Start 40 mg day, increase 20 –
40 mg/day up to 160 mg

Spironolactone:
§ Onset of action 2 – 5 days
§ Dose: 100 - 400 mg/day
§ Start 100 – 200 mg/day, increase
every 5 – 7 days up to 400 mg
Aldosterone antagonist
Longer to work

Metolazone:
§ Dose: 2.5 – 10 mg/day
§ Start 2.5 mg day, increase up to
10 mg/day as tolerated

Titrate to response!
Measure abdominal girth
Urine output, what is taken in
Target a certain amount of loss per day

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Diuretics monitoring for efficacy

A

Weight, abdominal girth, ins and outs
Roughly 500 ml/day or 0.5 kg/day

Urine output, what is taken in
Target a certain amount of loss per day
titrating dose based on that

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Diuretics monitoring for toxicity

A

Electrolytes, serum creatinine, BUN, hypotension
furosemide, metolazone – uric acid, hyperglycemia, volume depletion
spironolactone – hyperkalemia, gynecomastia/mastalgia, muscle cramps

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

ascites non-pharm

A

rescit dietary Na+
restrict fluids to 1.5L/day
bedrest if severe or refractory

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

ascities parecentesis

flowchart

A

tap 3-4 L + nonpharm –> improvement = no med
no improvement –> spironolactone
improve –> continue spir

no improvement –? furosemide
improve –? continue spir + furos

no improvement –? metolazone
improve –? continue spir + furos + metolazone

if no improvement, continue 3 diuretics and perform weekly large vol paracentesis
if >5L is removed, infuse 6-8g/L albumin
consider TIPS

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

what is TIPS

A

transjugular intrahepatic portosystemic shunt

Metallic shunt connects portal vein t hepatic vein, bypasses the liver
Preventing backup and ascities

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Spontaneous Bacterial Peritonitis (SBP)

A
§ Occurs in 10 – 25 % of patients with
ascites
§ Infection of pre-existing ascitic fluid
in peritoneal cavity
§ Pathogens: E. coli, enterococcus, S.
pneumonia
§ Exact mechanism for inoculation
unknown
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

SBP Treatment:

prevention?

A
§ Empiric antibiotics:
3rd generation cephalosporins
(cefotaxime, ceftriaxone)
§ Adjust therapy based on culture results
of ascites fluid.

Prevention:
§ Trimethoprim/sulfamethoxazole or ciprofloxacin
§ May need long term if previous SBP
Watch for aby resistance, reserve for highest risk pt

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Esophageal Varices

what is it

A

§ Dilated and weakened blood vessels caused
by portal hypertension
§ Alternate routes of blood flow from the portal
to systemic circulation
§ Low pressure vessels handling high pressure
loads
§ Presence is correlated to disease severity

Portal HTN
Dilated blood vessels as pressure goes out to collateral channels
Dilation of rectal veins
Normally low pressure vessels that become engourged, can burst and blee

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

what are collaterals?

A
  • Esophageal varices
  • Umbilical vein to abdominal wall (caput medusa)
  • Rectal veins (internal mhemorrhoids
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Esophageal Varices

how is it diagnosed?

A

§ Diagnosed by endoscopy
§ About 20% mortality risk per episode
§ Risk of bleeding dependent on: severity
of liver disease, property of varix (size,
thickness of wall), previous history of
bleeding
§ Variceal bleeding can occur once portal
venous pressure exceeds 12 mmHg
(normal is around 4 mmHg)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Esophageal Varices: Goals

A

§ Primary Prevention: prevent the first bleeding episode
§ Acute Treatment: stabilize patient with an acute variceal hemorrhage
§ Secondary Prevention: prevent recurrence in someone who has already had a variceal bleed

17
Q

Primary Prophylaxis of Esophageal Varices
no varix
Varix < 5mm
Varix > 5mm

A

diagnosis of cirrhosis –> Screen patients for esophageal varices with endoscopy

No varix
Observe patient

Varix < 5mm
Prevention: Beta-blockers

Varix > 5mm
Beta-blockers/EVL (combination)

18
Q

Beta Blockers

B1 vs B2 blocking action

A

§ Reduce portal blood flow
§ Non-selective beta blockers preferred
–ie propranolol 10 – 20 mg po bid, nadolol 20 – 40 mg daily
§ Titrate dose to decrease resting heart rate by 25% or 55 – 60 bpm or development of adverse effects.

Beta1 block action – decrease CO, leads
to decrease portal perfusion
Beta2 block action – unopposed alphaadrenergic vasoconstriction, leads to decrease splanchnic perfusion

19
Q

bb monitoring

A

–Efficacy: decrease heart rate, lack of bleeding

–Toxicity: hypotension, bradycardia, fatigue, depression, nightmares

20
Q

Endoscopic Approaches
EVL
EIS

A

§ EVL: Endoscopic Variceal Ligation
–Placement of rubber bands around the varix
–Placed using a clear plastic channel attached to an endoscope
–Varix sloughs off after 2 – 3 days
§ EIS: Endoscopic injection sclerotherapy
–not as effective as beta-blockers/EVL, not used much

21
Q

Treatment of Acute Varices

agents used

A

§ Acute Variceal Bleeding is a medical emergency
§ Accounts of one-third of all deaths
§ Agents used include:
–Vasopressin – helps splanchnic vasoconstriction (quick vasoconstcition)
–Octreotide – synthetic analogue of somatostatin, inhibits the release of vasodilatory hormone (causes splanchnic vasoconstriction)
–Both are given as continuous IV infusions

22
Q
Treatment of Acute Varices
supportive
pharm
endoscopic
surgical
A

Supportive:Fluids +/- blood
Vitamin K/fresh frozen
plasma/platelets
Prophylactic antibiotics

Pharmacologic Options: Vasopressin, Octreotide
Endoscopic techniques: Sclerotherapy, Band ligation
Surgical: Sclerotherapy, Band ligation, TIPS

23
Q

Secondary Prevention of Varices

A

§ Risk of rebleeding is close to 80% (high)
§ Secondary prophylaxis includes:
–Non-selective beta blockers
–EVL
–Combination of both (most of the time)
–TIPS or shunt surgery for failed therapy

24
Q

Hepatic Encephalopathy (HE)

A

§ Metabolically induced disturbance on the brain, potentially reversible.
§ Accumulation of substances that are normally removed in the liver.
–Accumulation of gut derived nitrogenous substances such as ammonia (most common reason), another possible cause is decreased clearance
of GABA
§ Must distinguish HE from other causes associated with changes in cognition

25
Q

major risk factors of hepatic encephalopathy

A
TIPS, protal vein thrombosis
infections (SBP)
AKI, electrolyte derangements (dec K_)
GI bleed
hypoxemia, hyercapnia
26
Q

Treatment of HE
Lactulose

mechansim
monitoring

A

§ Mechanism: acidifies the GI tract (NH3 + H+ = NH4+)
§ Increased GI transit through osmotic effect.
§ Dose: 30 – 60 ml TID to QID, adjust dose to produce 2 – 3 soft stools per day, can be given oral, feeding tube, rectally avail

monitoring
Efficacy: number of bowel movements, neurological status
Toxicity: GI discomfort, diarrhea, dehydration

27
Q

Treatment of HE

Rifaximin

A

§ Mechanism: Reduces urease producing bacteria in
the gut = decrease in blood ammonia
§ Dose: 550 mg bid
§ Expensive, requires special authorization for ABC
would be long term use (more than 2 wks)

monitoring:
Efficacy: neurological status
Toxicity: GI discomfort, nausea, headache, dizziness, edema

28
Q

Treatment of HE

flowchart see slide 31

A

Give lactulose if HE
check improvement in 24-48 hours
Reoccur, give rifaximin

Futher recurrence, look at other thins, consider liver transplant )dont need to know this part)

29
Q

Treatment of HE

flowchart see slide 31

A

Give lactulose if HE
check improvement in 24-48 hours
Reoccur, give rifaximin

Futher recurrence, look at other thins, consider liver transplant (dont need to know this part)

30
Q

Pharmacokinetic Considerations in Liver Disease

Patient factors:
§ Does the patient require this drug? At this dose? Is there an alternative?
§ How severe is the patient? What is the clinical status of the patient?
§ Is the patient liver function stable or changing?
§ What is the expected length of therapy?

Drug factors:
§ Is the drug eliminated via Phase I or Phase II?
§ Is there active metabolites?
§ How much (%) of the drug is eliminated by the hepatic route?
§ What are the consequences of not adjusting the dose?

A
§ Decrease clearance
§ Decrease in first pass effect
§ Decrease albumin
§ Increase volume of distribution in patients with ascites (esp polar drugs)
§ Increase half-life (T1/2 = Vd/Cl)

anticipate drug accumulation, enhanced effect

Start seeing effects on phase I earlier
If severely affected, will see both Phase I and II impacts
low E drugs dependent on intrisnic metabolism
high E dependent on blood flow
- both bloodflow and intrinsic metabolism is affected in pts with ESRD or severe disease